Fyn inhibition by cycloalkane-fused 1,2-dithiole-3-thiones enhances antioxidant capacity and protects mitochondria from oxidative injury

Molecular Pharmacology

Volumn 82, Issue 1, 2012, Pages 27-36

  Koo, Ja Hyun ^a   Lee, Woo Hyung ^a   Lee, Chan Gyu ^a   Kim, Sang Geon ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DITHIOLE 3 THIONE DERIVATIVE; 2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4,5,6,7 TETRAHYDROBENZO 1,2 DITHIOLE 3 THIONE; 5 (QUINOLIN 2 YL) 1,2 DITHIOLE 3 THIONE; 5 METHYL 1,2 DITHIOLE 3 THIONE; 5,6 DIHYDRO 4H CYCLOPENTA 1,2 DITHIOLE 3 THIONE; ARACHIDONIC ACID; CYCLOALKANE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IRON; PROTEIN KINASE FYN; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL;

AMP-ACTIVATED PROTEIN KINASES; ANTIOXIDANTS; ARACHIDONIC ACID; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CELLS, CULTURED; CYCLOPARAFFINS; HEP G2 CELLS; HUMANS; HYDROGEN PEROXIDE; IRON; MITOCHONDRIA; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-FYN; SUPEROXIDES; THIONES; THIOPHENES;

EID: 84862580442     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.077149     Document Type: Article

References (55)

1. Abe J and Berk BC (1999) Fyn and JAK2 mediate Ras activation by reactive oxygen species. J Biol Chem 274:21003-21010.
2. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, and Poniachik J (2004) Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 106:635-643. (Pubitemid 38797577)
3. Bae EJ, Yang YM, and Kim SG (2008) Abrogation of hyperosmotic impairment of insulin signaling by a novel class of 1,2-dithiole-3-thiones through the inhibition of S6K1 activation. Mol Pharmacol 73:1502-1512.
4. Bass SE, Sienkiewicz P, Macdonald CJ, Cheng RY, Sparatore A, Del Soldato P, Roberts DD, Moody TW, Wink DA, and Yeh GC (2009) Novel dithiolethione- modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells. Clin Cancer Res 15:1964-1972.
5. Bastie CC, Zong H, Xu J, Busa B, Judex S, Kurland IJ, and Pessin JE (2007) Integrative metabolic regulation of peripheral tissue fatty acid oxidation by the SRC kinase family member Fyn. Cell Metab 5:371-381.
6. Bieder A, Decouvelaere B, Gaillard C, Depaire H, Heusse D, Ledoux C, Lemar M, Le Roy JP, Raynaud L, and Snozzi C (1983) Comparison of the metabolism of oltipraz in the mouse, rat and monkey and in man. Distribution of the metabolites in each species. Arzneimittelforschung 33:1289-1297. (Pubitemid 13051120)
7. Bolton MG, Muñoz A, Jacobson LP, Groopman JD, Maxuitenko YY, Roebuck BD, and Kensler TW (1993) Transient intervention with oltipraz protects against aflatoxininduced hepatic tumorigenesis. Cancer Res 53:3499-3504. (Pubitemid 23229626)
8. Browning JD and Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147-152. (Pubitemid 39071617)
9. Büchner N, Altschmied J, Jakob S, Saretzki G, and Haendeler J (2010) Well-known signaling proteins exert new functions in the nucleus and mitochondria. Antioxid Redox Signal 13:551-558.
10. Choi SH, Kim YW, and Kim SG (2010) AMPK-mediated GSK3β inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress. Biochem Pharmacol 79:1352-1362.
11. Cocco T, Di Paola M, Papa S, and LorussoM(1999) Arachidonic acid interaction with the mitochondrial electron transport chain promotes reactive oxygen species generation. Free Radic Biol Med 27:51-59. (Pubitemid 29353083)
12. Cui QL, Zheng WH, Quirion R, and Almazan G (2005) Inhibition of Src-like kinases reveals Akt-dependent and -independent pathways in insulin-like growth factor I-mediated oligodendrocyte progenitor survival. J Biol Chem 280:8918-8928. (Pubitemid 40409583)
13. Das S, Wong R, Rajapakse N, Murphy E, and Steenbergen C (2008) Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ Res 103:983-991.
14. Donlin LT, Roman CA, Adlam M, Regelmann AG, and Alexandropoulos K (2002) Defective thymocyte maturation by transgenic expression of a truncated form of the T lymphocyte adapter molecule and Fyn substrate, Sin. J Immunol 169:6900-6909. (Pubitemid 36899276)
15. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, and Mehrabian M (2004) Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350:29-37. (Pubitemid 38032181)
16. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, and Powell LW (1998) Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114:311-318. (Pubitemid 28093538)
17. Glintborg B, Weimann A, Kensler TW, and Poulsen HE (2006) Oltipraz chemoprevention trial in Qidong, People's Republic of China: unaltered oxidative biomarkers. Free Radic Biol Med 41:1010-1014. (Pubitemid 44247554)
18. Hayashi T, Hirshman MF, Fujii N, Habinowski SA, Witters LA, and Goodyear LJ (2000) Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism. Diabetes 49:527-531. (Pubitemid 30183739)
19. Hezel AF and Bardeesy N (2008) LKB1; linking cell structure and tumor suppression. Oncogene 27:6908-6919.
20. Ido Y, Carling D, and Ruderman N (2002) Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 51:159-167. (Pubitemid 34517993)
21. Isenberg JS, Jia Y, Field L, Ridnour LA, Sparatore A, Del Soldato P, Sowers AL, Yeh GC, Moody TW, Wink DA, et al. (2007) Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br J Pharmacol 151:63-72.
22. Jacobson LP, Zhang BC, Zhu YR, Wang JB, Wu Y, Zhang QN, Yu LY, Qian GS, Kuang SY, Li YF, et al. (1997) Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev 6:257-265. (Pubitemid 27172891)
23. Kang KW, Cho IJ, Lee CH, and Kim SG (2003) Essential role of phosphatidylinositol 3-kinase-dependent CCAAT/enhancer binding protein β activation in the induction of glutathione S-transferase by oltipraz. J Natl Cancer Inst 95:53-66. (Pubitemid 36124296)
24. Kay HY, Kim YW, Ryu da H, Sung SH, Hwang SJ, and Kim SG (2011) Nrf2-mediated liver protection by sauchinone, an antioxidant lignan, from acetaminophen toxicity through the PKCδ-GSK3β pathway. Br J Pharmacol 163:1653-1665.
25. Kay HY, Won Yang J, Kim TH, Lee da Y, Kang B, Ryu JH, Jeon R, and Kim SG (2010) Ajoene, a stable garlic by-product, has an antioxidant effect through Nrf2-mediated glutamate-cysteine ligase induction in HepG2 cells and primary hepatocytes. J Nutr 140:1211-1219.
26. Kensler TW and Wakabayashi N (2010) Nrf2: friend or foe for chemoprevention? Carcinogenesis 31:90-99.
27. Kim SG, Kim YM, Choi YH, Lee MG, Choi JY, Han JY, Cho SH, Jang JW, Um SH, Chon CY, et al. (2010) Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-β1. Clin Pharmacol Ther 88:360-368.
28. Kim YW, Lee SM, Shin SM, Hwang SJ, Brooks JS, Kang HE, Lee MG, Kim SC, and Kim SG (2009) Efficacy of sauchinone as a novel AMPK-activating lignan for preventing iron-induced oxidative stress and liver injury. Free Radic Biol Med 47:1082-1092.
29. Kockeritz L, Doble B, Patel S, and Woodgett JR (2006) Glycogen synthase kinase-3: an overview of an over-achieving protein kinase. Curr Drug Targets 7:1377-1388. (Pubitemid 44718298)
30. Kumar S and Bandyopadhyay U (2005) Free heme toxicity and its detoxification systems in human. Toxicol Lett 157:175-188. (Pubitemid 40726102)
31. Liu XM, Peyton KJ, Shebib AR, Wang H, Korthuis RJ, and Durante W (2011) Activation of AMPK stimulates heme oxygenase-1 gene expression and human endothelial cell survival. Am J Physiol Heart Circ Physiol 300:H84-H93.
32. Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, et al. (2009) Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res 69:6889-6898.
33. McLaren CE, Gordeuk VR, Looker AC, Hasselblad V, Edwards CQ, Griffen LM, Kushner JP, and Brittenham GM (1995) Prevalence of heterozygotes for hemochromatosis in the white population of the United States. Blood 86:2021-2027.
34. Mustelin T, Pessa-Morikawa T, Autero M, Gassmann M, Andersson LC, Gahmberg CG, and Burn P (1992) Regulation of the p59fyn protein tyrosine kinase by the CD45 phosphotyrosine phosphatase. Eur J Immunol 22:1173-1178.
35. Nguyen T, Yang CS, and Pickett CB (2004) The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 37:433-441. (Pubitemid 38901076)
36. Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh K, Ohori K, Hotta H, Terashima Y, and Shimamoto K (2007) Modulation of the mitochondrial permeability transition pore complex in GSK-3β-mediated myocardial protection. J Mol Cell Cardiol 43:564-570. (Pubitemid 47615050)
37. O'Dwyer PJ, Clayton M, Halbherr T, Myers CB, and Yao K (1997) Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells. Clin Cancer Res 3:783-791. (Pubitemid 27244347)
38. O'Dwyer PJ, Szarka C, Brennan JM, Laub PB, and Gallo JM (2000) Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose. Clin Cancer Res 6:4692-4696. (Pubitemid 32110406)
39. Pariser H, Ezquerra L, Herradon G, Perez-Pinera P, and Deuel TF (2005) Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase β/ζ-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem Biophys Res Commun 332:664-669. (Pubitemid 40745166)
40. Parsons SJ and Parsons JT (2004) Src family kinases, key regulators of signal transduction. Oncogene 23:7906-7909. (Pubitemid 39468849)
41. Peters DJ, McGrew BR, Perron DC, Liptak LM, and Laudano AP (1990) In vivo phosphorylation and membrane association of the fyn proto-oncogene product in IM-9 human lymphoblasts. Oncogene 5:1313-1319.
42. Ricci JE, Lang V, Luciano F, Belhacene N, Giordanengo V, Michel F, Bismuth G, and Auberger P (2001) An absolute requirement for Fyn in T cell receptor-induced caspase activation and apoptosis. FASEB J 15:1777-1779.
43. Salazar M, Rojo AI, Velasco D, de Sagarra RM, and Cuadrado A (2006) Glycogen synthase kinase-3β inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem 281:14841-14851. (Pubitemid 43855189)
44. Sandilands E, Brunton VG, and Frame MC (2007) The membrane targeting and spatial activation of Src, Yes and Fyn is influenced by palmitoylation and distinct RhoB/RhoD endosome requirements. J Cell Sci 120:2555-2564. (Pubitemid 47323864)
45. Scorrano L, Penzo D, Petronilli V, Pagano F, and Bernardi P (2001) Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-α apoptotic signaling. J Biol Chem 276:12035-12040.
46. Shin SM, Cho IJ, and Kim SG (2009) Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3β inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway. Mol Pharmacol 76:884-895.
47. Shin SM and Kim SG (2009) Inhibition of arachidonic acid and iron-induced mitochondrial dysfunction and apoptosis by oltipraz and novel 1,2-dithiole-3-thione congeners. Mol Pharmacol 75:242-253.
48. Simopoulos AP (2006) Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 60:502-507.
49. Tazzari V, Cappelletti G, Casagrande M, Perrino E, Renzi L, Del Soldato P, and Sparatore A (2010) New aryldithiolethione derivatives as potent histone deacetylase inhibitors. Bioorg Med Chem 18:4187-4194.
50. Terai K, Hiramoto Y, Masaki M, Sugiyama S, Kuroda T, Hori M, Kawase I, and Hirota H (2005) AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol 25:9554-9575. (Pubitemid 41507855)
51. Thompson TN (2001) Optimization of metabolic stability as a goal of modern drug design. Med Res Rev 21:412-449.
52. Wang JS, Shen X, He X, Zhu YR, Zhang BC, Wang JB, Qian GS, Kuang SY, Zarba A, Egner PA, et al. (1999) Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 91:347-354. (Pubitemid 29102334)
53. Yamada E, Pessin JE, Kurland IJ, Schwartz GJ, and Bastie CC (2010) Fyn-dependent regulation of energy expenditure and body weight is mediated by tyrosine phosphorylation of LKB1. Cell Metab 11:113-124.
54. Zamzami N and Kroemer G (2001) The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2:67-71. (Pubitemid 33676964)
55. Zhang Y and Munday R (2008) Dithiolethiones for cancer chemoprevention: where do we stand? Mol Cancer Ther 7:3470-3479.